標(biāo)題: Titlebook: Biology and Management of Multiple Myeloma; James R. Berenson Book 2004 Springer Science+Business Media New York 2004 Staging.anemia.bone [打印本頁(yè)] 作者: 類(lèi)屬 時(shí)間: 2025-3-21 19:41
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma影響因子(影響力)
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma被引頻次
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma被引頻次學(xué)科排名
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma年度引用
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma年度引用學(xué)科排名
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma讀者反饋
書(shū)目名稱(chēng)Biology and Management of Multiple Myeloma讀者反饋學(xué)科排名
作者: 保留 時(shí)間: 2025-3-21 22:49 作者: 問(wèn)到了燒瓶 時(shí)間: 2025-3-22 00:31
Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myelomah MM .. Barlogie and colleagues introduced the concept of high-dose chemotherapy followed by autologous stem cell transplantation in the 1980s . and rapidly several large trials were performed in patients with MM ..作者: 狂怒 時(shí)間: 2025-3-22 06:12 作者: inquisitive 時(shí)間: 2025-3-22 12:38
New Therapeutic Approaches to Myeloma,lan-prednisone (MP) combination therapy, a number of cytotoxic drug combinations have been investigated. A popular example is the M2 protocol, consisting of vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) ..作者: Affable 時(shí)間: 2025-3-22 16:16
Sprechweisen in der (Konflikt)Moderationd that a less mature B lymphocyte or even a primordial stem cell might be clonal .. In this proposed model, these precursor cells could then sustain the plasma cell pool through differentiation in a manner akin to the process that occurs in chronic myelogenous leukemia. Recent advances in molecular 作者: Sad570 時(shí)間: 2025-3-22 20:20
Gesellschaftspolitik und Staatst?tigkeitdirect measures of tumor bulk and activity such as hemoglobin, calcium, serum and urine M-protein levels, number of bone lesions, and creatinine levels. Combining a series of inaccurate measures of tumor burden has proved to have limitations. In particular, quantification of bone lesions is unreliab作者: 發(fā)酵劑 時(shí)間: 2025-3-23 00:36 作者: 外面 時(shí)間: 2025-3-23 02:17 作者: 易受騙 時(shí)間: 2025-3-23 07:15 作者: 憤慨點(diǎn)吧 時(shí)間: 2025-3-23 09:56 作者: 過(guò)分 時(shí)間: 2025-3-23 16:23
Eigene Haltung und innere Widerst?nde the production of immunoglobulin (Ig) (heavy and/or light chains) in a monoclonal fashion. The most common myelomas are IgG or IgA κ or λ, and κ or λ Bence Jones-only myeloma. Waldenstrom’s macroglobulinemia is IgM κ or λ in type.作者: EXPEL 時(shí)間: 2025-3-23 18:22
https://doi.org/10.1007/978-3-531-90811-3in approx 50 to 60% of patients with chronic myelocytic leukemia, a disease that so far has not been curable using any other treatment modalities .. Subgroups of patients with acute lymphoblastic leukemia ., chronic lymphocytic leukemia ., myelodysplastic syndrome ., and myelofibrosis . are also candidates for allogeneic transplantation.作者: hurricane 時(shí)間: 2025-3-24 00:25
Gesellschaftspolitik und Staatst?tigkeits achievement of stable disease. Not surprisingly, a long plateau phase is a strong indicator of long survival in multiple myeloma (MM) .. Short plateau phases are associated with short doubling times of the patients’ M-component and frequent resistance to salvage chemotherapy after relapse ..作者: elastic 時(shí)間: 2025-3-24 05:45
https://doi.org/10.1007/978-3-531-90811-3prolongation of a good quality of life for as long as possible. The treatment of MM should focus on the management of the complications of the disease, along with attempts to reduce the growth of malignant plasma cells.作者: 笨拙的你 時(shí)間: 2025-3-24 07:57 作者: 用手捏 時(shí)間: 2025-3-24 10:49 作者: onlooker 時(shí)間: 2025-3-24 17:40 作者: 準(zhǔn)則 時(shí)間: 2025-3-24 22:10 作者: 導(dǎo)師 時(shí)間: 2025-3-24 23:56 作者: 欲望小妹 時(shí)間: 2025-3-25 03:38 作者: Adornment 時(shí)間: 2025-3-25 11:03
Book 2004 On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi‘s sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clini作者: Hallmark 時(shí)間: 2025-3-25 13:53
2364-1134 ssion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.978-1-61737-143-1978-1-59259-817-5Series ISSN 2364-1134 Series E-ISSN 2364-1142 作者: CON 時(shí)間: 2025-3-25 18:14 作者: Cpr951 時(shí)間: 2025-3-25 20:11 作者: 吞下 時(shí)間: 2025-3-26 01:59 作者: 運(yùn)動(dòng)的我 時(shí)間: 2025-3-26 04:41
Renal Diseases Associated With Multiple Myeloma and Related Plasma Cell Dyscrasias,enal diseases associated with MM and related plasma cell dyscrasias, so that they may institute appropriate therapeutic measures, especially those that can reduce the production of the toxic immunoglobulins responsible for the devastating and ultimately fatal nature of there disorders.作者: amyloid 時(shí)間: 2025-3-26 09:20 作者: Recess 時(shí)間: 2025-3-26 14:52
Epidemiology of Multiple Myeloma and Related Disease, the production of immunoglobulin (Ig) (heavy and/or light chains) in a monoclonal fashion. The most common myelomas are IgG or IgA κ or λ, and κ or λ Bence Jones-only myeloma. Waldenstrom’s macroglobulinemia is IgM κ or λ in type.作者: BOLUS 時(shí)間: 2025-3-26 17:51 作者: motivate 時(shí)間: 2025-3-26 23:03 作者: vascular 時(shí)間: 2025-3-27 03:39 作者: IRATE 時(shí)間: 2025-3-27 08:11
Diagnosis of Multiple Myeloma,arrow. Frequently, the myeloma invades adjacent bone, destroying skeletal structures and resulting in bone pain and fractures. Occasionally, plasma cells infiltrate multiple organs and produce other symptoms. The excessive production of a monoclonal (M) protein can lead to renal failure caused by Be作者: CLAY 時(shí)間: 2025-3-27 09:33 作者: Subdue 時(shí)間: 2025-3-27 14:15
Characterization of the Myeloma Clone, lymphocytes all produce an identical immunoglobulin known as a monoclonal protein, the laboratory hallmark of this malignancy. Because MM is typically disseminated throughout the body at diagnosis, malignant cells must also exist, even if transiently, within the circulation as well. Although plasma作者: 枯燥 時(shí)間: 2025-3-27 20:13
Oncogenesis of Multiple Myeloma,hts into the biology and molecular pathology of the disease have suggested that MM originates from a somatically mutated and isotype-switched follicle-center B cell that has retained its ability to differentiate into a plasma cell homing to the bone marrow. Initiation and progression of the disease 作者: Fallibility 時(shí)間: 2025-3-27 22:59
Cytokines in Multiple Myeloma,re their survival is strongly dependent on the normal stromal cells that secrete cytokines and interact with the malignant cells through adhesion molecules. This chapter briefly summarizes the main features of normal plasma cell development. It will then consider recent information on the cytokines 作者: 牽索 時(shí)間: 2025-3-28 03:18
Monoclonal Gammopathy of Undetermined Significance,n). Each M protein consists of two heavy polypeptide chains of the same class and subclass and two light polypeptide chains of the same type. The heavy polypeptide chains are γin immunoglobulin (Ig) G, a in IgA, α in IgM, δ in IgD, and ε in IgE. The light-chain types are κ and λ.作者: 陳腐的人 時(shí)間: 2025-3-28 09:09
Tumor Burden,rs from that in solid tumors such as lymphoma, where direct assessment of tumor mass is often possible. In myeloma, measures used to quantitate tumor burden are almost all indirect and response to therapy difficult to quantify. The percentage of plasma cells in the bone marrow could be considered a 作者: TEN 時(shí)間: 2025-3-28 10:46 作者: Offset 時(shí)間: 2025-3-28 17:30 作者: Fallibility 時(shí)間: 2025-3-28 22:40 作者: Keratectomy 時(shí)間: 2025-3-29 00:03
Remission Maintenance in Multiple Myeloma,eau”— phase of variable length, a cytokinetically quiescent state . in which myeloma cell proliferation is balanced by myeloma cell death. Complete or partial remission is not an absolute prerequisite for a plateau phase, which can be observed in patients whose best response to induction treatment i作者: 鋼筆尖 時(shí)間: 2025-3-29 03:08 作者: 圖畫(huà)文字 時(shí)間: 2025-3-29 10:31
Renal Diseases Associated With Multiple Myeloma and Related Plasma Cell Dyscrasias,ni syndrome (AFS) represent a group of disorders characterized by the presence of monoclonal plasma cells in bone marrow and their homogeneous immunoglobulin products—i.e., M proteins—in serum, urine, or both .. These immunoglobulin components can be nephrotoxic, as evidenced by their propensity to 作者: scrape 時(shí)間: 2025-3-29 14:29 作者: Surgeon 時(shí)間: 2025-3-29 18:30
New Therapeutic Approaches to Myeloma,icians have found that the most effective drugs for the treatment of myeloma belong to the following pharmacologic classes: alkylating agents (melphalan, cyclophosphamide, 1,3-bis-[2-chloroethyl]-1-nitrosurea [BCNU]), topoisomerase II inhibitors (doxorubicin and etoposide), glucocorticoids (predniso作者: 碎片 時(shí)間: 2025-3-29 22:37 作者: hallow 時(shí)間: 2025-3-30 03:57
978-1-61737-143-1Springer Science+Business Media New York 2004作者: 攤位 時(shí)間: 2025-3-30 07:50
Biology and Management of Multiple Myeloma978-1-59259-817-5Series ISSN 2364-1134 Series E-ISSN 2364-1142 作者: Notify 時(shí)間: 2025-3-30 11:43 作者: Root494 時(shí)間: 2025-3-30 14:25 作者: 騷擾 時(shí)間: 2025-3-30 19:00
Immunological Approaches to Multiple Myeloma,Tumor cells express tumor-associated protein antigens on the cell surface, as well as peptides of the protein presented in the groove of the major histocompatibility complex (MHC). Although most tumor antigens are shared self-antigens, they can be regarded as tumor-specific antigens and used as targets for immunotherapy.作者: Gossamer 時(shí)間: 2025-3-30 21:03 作者: antecedence 時(shí)間: 2025-3-31 01:03
Vorbesprechung, Rahmen- und Akteursplanungarrow. Frequently, the myeloma invades adjacent bone, destroying skeletal structures and resulting in bone pain and fractures. Occasionally, plasma cells infiltrate multiple organs and produce other symptoms. The excessive production of a monoclonal (M) protein can lead to renal failure caused by Be作者: verdict 時(shí)間: 2025-3-31 07:55
Eigene Haltung und innere Widerst?ndesorders are Waldenstrom’s macroglobulinemia, the heavy-chain diseases, primary systemic amyloidosis, and systemic light-chain deposition disease. The characteristic feature of these diseases is the involvement of cells that are either plasma cells or lymphocytes resembling plasma cells and typically作者: 厭倦嗎你 時(shí)間: 2025-3-31 09:51
Sprechweisen in der (Konflikt)Moderation lymphocytes all produce an identical immunoglobulin known as a monoclonal protein, the laboratory hallmark of this malignancy. Because MM is typically disseminated throughout the body at diagnosis, malignant cells must also exist, even if transiently, within the circulation as well. Although plasma
